1. Home
  2. IRD vs AERT Comparison

IRD vs AERT Comparison

Compare IRD & AERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRD
  • AERT
  • Stock Information
  • Founded
  • IRD 2018
  • AERT 2012
  • Country
  • IRD United States
  • AERT Singapore
  • Employees
  • IRD N/A
  • AERT N/A
  • Industry
  • IRD
  • AERT Professional Services
  • Sector
  • IRD
  • AERT Consumer Discretionary
  • Exchange
  • IRD NYSE
  • AERT Nasdaq
  • Market Cap
  • IRD 35.7M
  • AERT 25.4M
  • IPO Year
  • IRD N/A
  • AERT N/A
  • Fundamental
  • Price
  • IRD $0.93
  • AERT $0.61
  • Analyst Decision
  • IRD Strong Buy
  • AERT
  • Analyst Count
  • IRD 1
  • AERT 0
  • Target Price
  • IRD $8.00
  • AERT N/A
  • AVG Volume (30 Days)
  • IRD 141.6K
  • AERT 79.6K
  • Earning Date
  • IRD 03-25-2025
  • AERT 02-14-2025
  • Dividend Yield
  • IRD N/A
  • AERT N/A
  • EPS Growth
  • IRD N/A
  • AERT N/A
  • EPS
  • IRD N/A
  • AERT 0.47
  • Revenue
  • IRD $8,381,000.00
  • AERT $70,851,000.00
  • Revenue This Year
  • IRD N/A
  • AERT N/A
  • Revenue Next Year
  • IRD $29.37
  • AERT N/A
  • P/E Ratio
  • IRD N/A
  • AERT $1.23
  • Revenue Growth
  • IRD N/A
  • AERT 4.38
  • 52 Week Low
  • IRD $0.81
  • AERT $0.46
  • 52 Week High
  • IRD $2.34
  • AERT $2.93
  • Technical
  • Relative Strength Index (RSI)
  • IRD N/A
  • AERT 49.83
  • Support Level
  • IRD N/A
  • AERT $0.56
  • Resistance Level
  • IRD N/A
  • AERT $0.68
  • Average True Range (ATR)
  • IRD 0.00
  • AERT 0.08
  • MACD
  • IRD 0.00
  • AERT 0.01
  • Stochastic Oscillator
  • IRD 0.00
  • AERT 56.23

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

About AERT Aeries Technology Inc.

Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs.

Share on Social Networks: